drugset / Trial / NCT02962388
The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line
Phase 2/3
Terminated
13 enrolled
French Innovative Leukemia Organisation
Novartis Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Prospective national multicenter randomized open label phase IIb RUXBETA trial.
Timeline
- Start
- 2017-01-03
- Primary completion
- 2021-06-28
- Completion
- 2021-06-28
Outcome
Outcome not reported
Stopped (Enrollment): “not enough recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Anagrelide | Small molecule | — | — |
| Subject | Ruxolitinib | Small molecule | 10 mg | Oral |